© 1998 American Heart Association, Inc.
Editorial |
Lessons From Human Arteries
How to Design a Gene Therapy Strategy for Treatment of Cardiovascular Disease
Correspondence to Ryuichi Morishita, MD, PhD, Assistant Professor, Department of Geriatric Medicine, Chief, Section of Gene Therapy, Osaka University Medical School, 2–2 Yamada-oka, Suita, Osaka 565, Japan. E-mail morishit@geriat.med.osaka-u.ac.jp
Key Words: restenosis • atherosclerosis • gene therapy • organ culture • adenovirus
Gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease, such as restenosis after angioplasty, vascular bypass graft occlusion, and transplant coronary vasculopathy, for which no known effective therapy exists. The first federally approved human gene therapy protocol started on September 14, 1990, in adenosine deaminase–deficienct patients.1 2 Eight years since the commencement of the first trial, >250 clinical studies of gene therapy are under investigation. In the cardiovascular field, >5 protocols have been approved. More recently, Isner and colleagues3 4 have demonstrated the utility of gene therapy using an angiogenic growth factor (vascular endothelial growth factor [VEGF]) for the treatment of critical limb ischemia in human patients. A reendothelialization strategy using the VEGF gene has also been tested in a clinical trial for the treatment of restenosis after angioplasty.5 The objectives were generally to evaluate (1) the in vivo efficacy of the gene transfer method, (2) the safety of the gene transfer method, and (3) the possible therapeutic efficacy. Although there are still many unresolved issues, human gene therapy for cardiovascular disease is now becoming a reality. Nevertheless, gene therapy still requires efficient in vivo gene transfer technology to achieve the final goal. During the past decade, many gene transfer methods, including viral transfer techniques such as the adenoviral method, have been developed, and some are being applied clinically in human gene therapy studies.
In addition to these issues, it is time to take a hard look at
practical issues that will determine the real clinical potential.
This article has been cited by other articles:
 |
|
 |
|
  T. Yamaoka, Y. Yonemitsu, K. Komori, H. Baba, T. Matsumoto, T. Onohara, and Y. Maehara Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1865 - H1872. [Abstract] [Full Text] [PDF]
|
|